Antibiotic-resistant enterococcal infections are a major concern in hospitals where patients with compromised immunity are readily infected. Enterococcus faecium bacteria are of particular interest as these pathogens account for over 80% of vancomycinresistant enterococcal infections. Antimicrobial peptides (AMPs) produced at the site of infection by engineered bacteria may offer a potential alternative to traditional antibiotics for the treatment of resistant bacteria such as E. faecium. For this mode of delivery to be effective, it is essential to identify a suitable protein expression system that can be used in the desired delivery bacterium. In this study, we describe a promising chloride-inducible promoter and its application in the bacterial delivery of AMPs from Lactococcus lactis to reduce counts of E. faecium bacteria in vitro. Reporter gene studies show that at chloride concentrations found within the human intestines, the chloride-inducible promoter exhibits high levels of protein expression compared to those of the commonly used nisin-inducible promoter. These results indicate that this system is powerful and would not require the exogenous administration of an inducer molecule. In its application for AMP production against E. faecium in vitro, L. lactis producing AMPs under the chloride promoter rapidly decreased E. faecium counts by nearly 10,000-fold. As an extension of this application, we also demonstrate the potential in using this type of delivery system in combination with traditional antibiotics to slow the development of resistance. Collectively, this study shows the promise of using a chloride-inducible promoter for the bacterial delivery of AMPs in the body for the treatment of vancomycin-resistant enterococci (VRE) and other antibiotic-resistant bacteria. E nterococcal infections are a rising concern for health care due to the increasing frequency of multidrug-resistant cases. As of 2013, nearly 30% of all reported enterococcal infections were antibiotic resistant (1). This high percentage of resistance is especially disconcerting in hospitals because patients with compromised immune systems or patients who are on antibiotic regimens are particularly susceptible to enterococcal infections (2). Once an infection has occurred, it can be difficult to eradicate not only from the infected patient but also from the entire hospital environment. Antibiotic resistance makes this process even more challenging, and these infections become both more dangerous and costly (3).Enterococcus faecium and Enterococcus faecalis are the causative pathogens of nearly all vancomycin-resistant enterococcal infections (4). While E. faecalis is more prevalent as an infectious agent, E. faecium is more commonly resistant to antibiotics than E. faecalis and is known for its ability to rapidly transfer antibiotic resistance (2). For example, nearly 81% of E. faecium infections are considered vancomycin resistant (VR), compared to only 5% of E. faecalis infections (4). Additionally, E. faecium carrying resistance to ...